RELMADA THERAPEUTICS, INC.: 10-Q filed 2022-11-10

Name: RELMADA THERAPEUTICS, INC.: 10-Q filed 2022-11-10
Creator: RELMADA THERAPEUTICS, INC.

What RELMADA THERAPEUTICS, INC. reported in its quarterly report filed 2022-11-10 (fiscal Q3 2022): 28 published measures, 86 facts as tagged in accession 0001213900-22-071154.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-10
Fiscal period: fiscal Q3 2022
Accession: 0001213900-22-071154 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All RELMADA THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	187,122,008	USD
At 2021-12-31	223,325,811	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	166,344,855	USD
At 2022-06-30	196,851,331	USD
At 2022-03-31	210,398,132	USD
At 2021-12-31	208,264,886	USD
At 2021-09-30	72,687,091	USD
At 2021-06-30	96,852,557	USD
At 2021-03-31	91,147,128	USD
At 2020-12-31	105,582,746	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-39,418,707	USD	92
2022-01-01 to 2022-09-30	-119,099,458	USD	273
2022-04-01 to 2022-06-30	-39,934,968	USD	91
2022-01-01 to 2022-03-31	-39,745,783	USD	90
2021-07-01 to 2021-09-30	-42,606,191	USD	92
2021-01-01 to 2021-09-30	-91,373,316	USD	273
2021-04-01 to 2021-06-30	-26,551,944	USD	91
2021-01-01 to 2021-03-31	-22,215,181	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-67,918,717	USD	273
2021-01-01 to 2021-09-30	-54,213,231	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	44,610,591	USD	273
2021-01-01 to 2021-09-30	26,102,432	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	21,389,056	USD	273
2021-01-01 to 2021-09-30	37,064,696	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-424,166,570	USD
At 2021-12-31	-305,067,112	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	30,063,735	shares	92
2022-01-01 to 2022-09-30	29,470,198	shares	273
2021-07-01 to 2021-09-30	17,478,477	shares	92
2021-01-01 to 2021-09-30	17,038,583	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	30,063,735	shares	92
2022-01-01 to 2022-09-30	29,470,198	shares	273
2021-07-01 to 2021-09-30	17,478,477	shares	92
2021-01-01 to 2021-09-30	17,038,583	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1.31	USD/shares	92
2022-01-01 to 2022-09-30	-4.04	USD/shares	273
2021-07-01 to 2021-09-30	-2.44	USD/shares	92
2021-01-01 to 2021-09-30	-5.36	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1.31	USD/shares	92
2022-01-01 to 2022-09-30	-4.04	USD/shares	273
2021-07-01 to 2021-09-30	-2.44	USD/shares	92
2021-01-01 to 2021-09-30	-5.36	USD/shares	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	32,568,836	USD	273
2021-01-01 to 2021-09-30	22,133,630	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-38,737,161	USD	92
2022-01-01 to 2022-09-30	-122,546,656	USD	273
2021-07-01 to 2021-09-30	-42,653,635	USD	92
2021-01-01 to 2021-09-30	-91,520,718	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	187,105,913	USD
At 2021-12-31	223,297,518	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	20,777,153	USD
At 2021-12-31	15,060,925	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-09-30	10,425,841	USD
At 2021-12-31	11,192,502	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	38,737,161	USD	92
2022-01-01 to 2022-09-30	122,546,656	USD	273
2021-07-01 to 2021-09-30	42,653,635	USD	92
2021-01-01 to 2021-09-30	91,520,718	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	30,529,108	USD	92
2022-01-01 to 2022-09-30	86,454,632	USD	273
2021-07-01 to 2021-09-30	33,993,974	USD	92
2021-01-01 to 2021-09-30	65,347,708	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit
At 2022-09-30	28,641,991	shares
At 2022-09-20	1,452,016	shares
At 2021-12-31	27,740,147	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-09-30	590,482,783	USD
At 2021-12-31	513,304,258	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2022-09-30	166,344,855	USD
At 2021-12-31	208,264,886	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2022-09-30	16,095	USD
At 2021-12-31	28,293	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2022-09-30	10,351,312	USD
At 2021-12-31	3,868,423	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	8,208,053	USD	92
2022-01-01 to 2022-09-30	36,092,024	USD	273
2021-07-01 to 2021-09-30	8,659,661	USD	92
2021-01-01 to 2021-09-30	26,173,010	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	1,258	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-681,546	USD	92
2022-01-01 to 2022-09-30	3,447,198	USD	273
2021-07-01 to 2021-09-30	47,444	USD	92
2021-01-01 to 2021-09-30	147,402	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	42,728,599	USD	273
2021-01-01 to 2021-09-30	23,416,036	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-766,661	USD	273
2021-01-01 to 2021-09-30	4,362,071	USD	273

Inspect the source

Entity: RELMADA THERAPEUTICS, INC. / CIK 0001553643
Captured: 2026-09-19T11:18:56.464Z
SEC response SHA-256: 34acb6579adb694402af1f940d83014f7841c8cf763b03e27ee64d386466bb53

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001553643.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))